FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
3 No-Brainer Growth Stocks to Buy in October
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
How a medtech market opportunity is shaping up for wearable neurotech
When you think of brain stimulating medtech, startups building wearables as therapeutics probably aren't the first thing that ...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Detailed price information for Rhythm Pharmaceuticals Inc (RYTM-Q) from The Globe and Mail including charting and trades.
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT) are both up-and-coming biotechs with no sales ...
The Jerusalem Post Blogs7h
Best Ozempic Alternatives to Burn Fat Naturally: OTC Compounded Semaglutide Options to Try
With so many treatments and drugs accessible, compounded semaglutide has recently ... I emphasized items manufactured in ...
You can now dress up as a ‘sexy Ozempic shot’ this Halloween
An online store has jumped on the Ozempic craze by releasing a “sexy” semaglutide injection costume just in time for ...
Morningstar16h
Obesity Drug Market: The Next Wave of GLP-1 Competition
New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...
Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU)
In a report released on October 10, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research ...